Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

about

Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.

P2860

Q53685792-887D6D8E-ED86-4834-95EE-0CE8CA3BEE90

P2860

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

Item

http://www.wikidata.org/entity/Q41551635

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Fulvestrant 500 milligrams as ...... ospective observational trial.

@en

type

Item

label

Fulvestrant 500 milligrams as ...... ospective observational trial.

@en

prefLabel

Fulvestrant 500 milligrams as ...... ospective observational trial.

@en

P1476

Fulvestrant 500 milligrams as ...... rospective observational trial

@en

P2093

Angela Vaccaro

http://www.w3.org/2001/XMLSchema#string

Antonino Grassadonia

http://www.w3.org/2001/XMLSchema#string

Carmine Roma

http://www.w3.org/2001/XMLSchema#string

Elena Iattoni

http://www.w3.org/2001/XMLSchema#string

Enzo Maria Ruggeri

http://www.w3.org/2001/XMLSchema#string

Giuliana D'Auria

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Lucia Mentuccia

http://www.w3.org/2001/XMLSchema#string

Maria Agnese Fabbri

http://www.w3.org/2001/XMLSchema#string

Mariella Mauri

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.

P304

54528-54536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17262

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903361

http://www.w3.org/2001/XMLSchema#string

P932

5589600

http://www.w3.org/2001/XMLSchema#string

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

about

P2860

P2860

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932